ADAM 12 and PAPP-A at 14-17 weeks' gestation as biomarkers of pre-eclampsia

Prenatal Diagnosis

Volumn 31, Issue 6, 2011, Pages 602-604

  D'Anna, R ^a   Baviera, G ^a   Giordano, D ^a   Russo, S ^a   Santamaria, A ^a   Granese, R ^a   Corrado, F ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

ADAM 12; PAPP A; Pre eclampsia

Indexed keywords

ADAM PROTEIN; BIOLOGICAL MARKER; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEIN ADAM 12; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMAN; MATERNAL BLOOD; PREECLAMPSIA; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ADAM PROTEINS; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MEMBRANE PROTEINS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROGNOSIS;

EID: 79956275313     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2737     Document Type: Article

References (14)

1. Bersinger NA, Odegard RA. 2004. Second- and third-trimester serum levels of placental proteins in preeclampsia and small for gestational age pregnancies. Acta Obstet Gynecol Scand 83: 37-45.
2. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin J-M. 2001. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 20: IX-XIV.
3. Carty DM, Delles C, Dominiczak AF. 2008. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med 18: 186-194.
4. D'Anna R, Baviera G, Giordano D, et al. 2009. First trimester serum PAPP-A and NGAL in the prediction of late-onset pre-eclampsia. Prenat Diagn 29: 1066-1068.
5. Hanley JA, McNeil BJ. 1983. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843.
6. Laigaard J, Sorensen T, Placing S, et al. 2005. Reduction of the disintegrin and metalloprotease ADAM 12 in preeclampsia. Obstet Gynecol 106: 144-149.
7. Lawrence JB, Oxvig C, Overgaard MT, et al. 1999. The insuline-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 96: 3149-3153.
8. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM. 2000. ADAM 12 cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 278: 511-515.
9. Poon LCY, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH. 2008. First-trimester maternal serum a Disintegrin and Metalloprotease 12 (ADAM 12) and adverse pregnancy outcome. Obstet Gynecol 112: 1082-1090.
10. Poon LCY, Maiz N, Valencia C, Plasencia W, Nicolaides KH. 2009. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 33: 23-33.
11. Spencer K, Cowans NJ, Stamatopoulou A. 2008. ADAM 12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 28: 212-216.
12. Spencer K, Yu CK, Savvidou M, Papageorghiu AT, Nicolaides KH. 2006. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation. Ultrasound Obstet Gynecol 27: 658-663.
13. Wald NJ, Morris JK, Ibison J, Wu T, George LM. 2006. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers. Prenat Diagn 26: 559-564.
14. Walker JJ. 2000. Pre-eclampsia. Lancet 356: 1260-1265.